Published in Circulation on October 01, 1986
Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. J Clin Invest (1997) 2.93
Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med (2013) 2.60
Myosin heavy chain gene expression in human heart failure. J Clin Invest (1997) 2.39
Myofibroblast and endothelial cell proliferation during murine myocardial infarct repair. Am J Pathol (2003) 2.22
Post-infarct remodelling: contribution of wound healing and inflammation. Cardiovasc Res (2008) 1.80
Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. J Clin Invest (1998) 1.73
Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. Heart Fail Rev (2011) 1.49
Cardiac remodeling at the population level--risk factors, screening, and outcomes. Nat Rev Cardiol (2011) 1.43
Enhanced efferocytosis of apoptotic cardiomyocytes through myeloid-epithelial-reproductive tyrosine kinase links acute inflammation resolution to cardiac repair after infarction. Circ Res (2013) 1.27
Cardiac mTOR protects the heart against ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol (2012) 1.20
Neuroendocrine activation after acute myocardial infarction. Br Heart J (1988) 1.16
Morphological aspects of apoptosis in heart diseases. J Cell Mol Med (2006) 1.09
Infarct size reduction and attenuation of global left ventricular remodeling with the CorCap cardiac support device following acute myocardial infarction in sheep. Heart Fail Rev (2005) 1.06
Surgical ventricular restoration to reverse left ventricular remodeling. Curr Cardiol Rev (2010) 1.03
Myocyte cellular hypertrophy and hyperplasia contribute to ventricular wall remodeling in anemia-induced cardiac hypertrophy in rats. Am J Pathol (1992) 1.02
Matrix metalloproteinases and myocardial infarction. Can J Cardiol (2007) 1.01
Left Ventricular Dyssynchrony After Acute Myocardial Infarction is a Powerful Indicator of Left Ventricular Remodeling. Korean Circ J (2009) 0.98
Favorable left ventricular remodeling following large myocardial infarction by exercise training. Effect on ventricular morphology and gene expression. J Clin Invest (1995) 0.97
Quantifying acute myocardial injury using ratiometric fluorometry. IEEE Trans Biomed Eng (2008) 0.96
Scarred myocardium imposes additional burden on remote viable myocardium despite a reduction in the extent of area with late contrast MR enhancement. Eur Radiol (2005) 0.96
Sirtuin1-p53, forkhead box O3a, p38 and post-infarct cardiac remodeling in the spontaneously diabetic Goto-Kakizaki rat. Cardiovasc Diabetol (2010) 0.94
Myocardial viability: impact on left ventricular dilatation after acute myocardial infarction. Heart (2002) 0.93
Chronic coronary artery constriction leads to moderate myocyte loss and left ventricular dysfunction and failure in rats. J Clin Invest (1992) 0.91
Ventricular dilatation in the absence of ACE inhibitors: influence of haemodynamic and neurohormonal variables following myocardial infarction. Heart (1999) 0.90
Post myocardial infarction of the left ventricle: the course ahead seen by cardiac MRI. Cardiovasc Diagn Ther (2012) 0.88
Angiotensin converting enzyme inhibitor prevents left ventricular remodelling after myocardial infarction in angiotensin II type 1 receptor knockout mice. Heart (2005) 0.88
Impact of microvascular integrity and local viability on left ventricular remodelling after reperfused acute myocardial infarction. Heart (2003) 0.86
Maladaptive hypertrophy after acute myocardial infarction positive effect of bone marrow-derived stem cell therapy on regional remodeling measured by cardiac MRI. Clin Res Cardiol (2011) 0.86
Image-based left ventricular shape analysis for sudden cardiac death risk stratification. Heart Rhythm (2014) 0.85
Cardiac mTOR rescues the detrimental effects of diet-induced obesity in the heart after ischemia-reperfusion. Am J Physiol Heart Circ Physiol (2015) 0.84
Association of ventricular arrhythmias with left ventricular remodelling after myocardial infarction. Heart (1997) 0.84
Non-uniform recovery of left ventricular transmural mechanics in ST-segment elevation myocardial infarction. Cardiovasc Ultrasound (2010) 0.83
Devices in the management of advanced, chronic heart failure. Nat Rev Cardiol (2012) 0.83
Management of mitral regurgitation during left ventricular reconstruction for ischemic heart failure. Eur J Cardiothorac Surg (2012) 0.83
Post-myocardial infarction left ventricular myocyte remodeling: are there gender differences in rats? Cardiovasc Pathol (2010) 0.83
Temporal influences on the prediction of postinfarction mortality by heart rate variability: a comparison with the left ventricular ejection fraction. Br Heart J (1994) 0.81
Two-dimensional speckle-tracking echocardiography assessment of left ventricular remodeling in patients after myocardial infarction and primary reperfusion. Arch Med Sci (2014) 0.81
Report of the Canadian Cardiovascular Society's consensus conference on the Management of the Postmyocardial Infarction Patient. CMAJ (1991) 0.80
Reverse left ventricular remodeling after acute myocardial infarction: the prognostic impact of left ventricular global torsion. Int J Cardiovasc Imaging (2012) 0.80
Modifying the mechanics of healing infarcts: Is better the enemy of good? J Mol Cell Cardiol (2015) 0.80
Thyroid hormones and cardiac remodeling. Heart Fail Rev (2016) 0.79
Short early filling deceleration time on day 1 after acute myocardial infarction is associated with short and long term left ventricular remodelling. Heart (2001) 0.79
Flow and myocardial interaction: an imaging perspective. Philos Trans R Soc Lond B Biol Sci (2007) 0.79
Noncoordinate regulation of alpha-1 adrenoreceptor coupling and reexpression of alpha skeletal actin in myocardial infarction-induced left ventricular failure in rats. J Clin Invest (1990) 0.79
Organ-conserving cardiac surgery. HSR Proc Intensive Care Cardiovasc Anesth (2013) 0.78
Physiological Implications of Myocardial Scar Structure. Compr Physiol (2015) 0.78
Congestive heart failure. New frontiers. West J Med (1991) 0.78
Effects of combined inhibition of the Na+-H+ exchanger and angiotensin-converting enzyme in rats with congestive heart failure after myocardial infarction. Br J Pharmacol (2005) 0.78
Why Is Infarct Expansion Such an Elusive Therapeutic Target? J Cardiovasc Transl Res (2015) 0.78
Intracardiac acoustic radiation force impulse (ARFI) and shear wave imaging in pigs with focal infarctions. IEEE Trans Ultrason Ferroelectr Freq Control (2013) 0.77
Inhibition of Na+-H+ exchange by cariporide reduces inflammation and heart failure in rabbits with myocardial infarction. Br J Pharmacol (2004) 0.77
Hyaluronan and cardiac regeneration. J Biomed Sci (2014) 0.77
Remodeling of the infarct territory in the time course of infarct healing in humans. MAGMA (2011) 0.76
Using MRI to predict future adverse cardiac remodelling in a male mouse model of myocardial infarction. Int J Cardiol Heart Vasc (2016) 0.76
Pathophysiology of heart failure: a look at the future. Tex Heart Inst J (1999) 0.76
Postmyocardial infarct remodeling and heart failure: potential contributions from pro- and antiaging factors. Cardiol Res Pract (2011) 0.76
Post myocardial infarction left ventricular dysfunction - assessment and follow up of patients undergoing surgical ventricular restoration by the endoventricular patchplasty. Indian Heart J (2013) 0.75
Ischaemic heart failure: is prevention in sight? Br Heart J (1993) 0.75
ACE inhibitors in acute and chronic ischaemia: current status and future promise. Br J Clin Pharmacol (1989) 0.75
Xinfuli Granule improves post-myocardial infarction ventricular remodeling and myocardial fibrosis in rats by regulating TGF-β/Smads signaling pathway. J Geriatr Cardiol (2017) 0.75
Long-acting calcium channel antagonist pranidipine prevents ventricular remodeling after myocardial infarction in rats. Heart Vessels (1999) 0.75
Surgical ventricular restoration: an operation to reverse remodeling - the basic science (part I). Curr Cardiol Rev (2009) 0.75
Can heart function lost to disease be regenerated by therapeutic targeting of cardiac scar tissue? Semin Cell Dev Biol (2016) 0.75
Effects on ventricular arrhythmias of oral captopril and of oral mononitrate started early in acute myocardial infarction: results of a randomised placebo controlled trial. Br Heart J (1993) 0.75
Different contribution of extent of myocardial injury to left ventricular systolic and diastolic function in early reperfused acute myocardial infarction. Cardiovasc Ultrasound (2014) 0.75
Prediction of Long-Term Survival in Patients with End-Stage Heart Failure Secondary to Ischemic Heart Disease: Surgical Correction and Volumetric Analysis. Ann Thorac Cardiovasc Surg (2015) 0.75
Effect of thrombolytic therapy on the incidence of early left ventricular infarct expansion in acute anterior myocardial infarction. Oman Med J (2011) 0.75
The pathophysiologic profile of congestive heart failure. Cardiovasc Drugs Ther (1988) 0.75
Function of remote non-infarcted myocardium after STEMI: analysis with cardiovascular magnetic resonance. Int J Cardiovasc Imaging (2012) 0.75
Native T1 value in the remote myocardium is independently associated with left ventricular dysfunction in patients with prior myocardial infarction. J Magn Reson Imaging (2017) 0.75
Nipradilol, a new beta-adrenergic blocker, reduces left ventricular remodeling following myocardial infarction in spontaneously hypertensive rats. Heart Vessels (1997) 0.75
The extent of akinesis is predictive of the in-hospital mortality from endoaneurysmorrhaphy. Z Kardiol (2005) 0.75
Early intervention in heart failure. Drugs (1990) 0.75
Adverse Remodeling and Reverse Remodeling After Myocardial Infarction. Curr Cardiol Rep (2017) 0.75
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med (1996) 23.76
Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation (1993) 9.24
Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest (1975) 5.72
A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med (1995) 4.94
Myocardial infarct size and ventricular function in rats. Circ Res (1979) 4.33
Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1999) 3.90
Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res (1987) 3.86
A comparison of management patterns after acute myocardial infarction in Canada and the United States. The SAVE investigators. N Engl J Med (1993) 3.75
Clinical significance of coronary arterial ectasia. Am J Cardiol (1976) 3.43
Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet (2000) 3.39
Increased coronary perforation in the new device era. Incidence, classification, management, and outcome. Circulation (1994) 3.30
Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation (1999) 3.26
Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1998) 3.19
Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med (1997) 3.13
Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis (1998) 3.09
Unaltered secretion of beta-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice. J Biol Chem (1997) 3.09
Paradoxical embolism. Diagnosis during life. Am J Med (1972) 2.85
Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation (2001) 2.80
Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation (1994) 2.74
Increased pulse pressure and risk of heart failure in the elderly. JAMA (1999) 2.74
Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators. N Engl J Med (1992) 2.72
Radiation exposure to patients undergoing diagnostic and interventional cardiac catheterization procedures. Cathet Cardiovasc Diagn (1997) 2.67
Clinical significance of mitral regurgitation after acute myocardial infarction. Survival and Ventricular Enlargement Investigators. Circulation (1997) 2.64
Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass. N Engl J Med (1996) 2.49
VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation (2000) 2.47
Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol (1991) 2.40
The influence of anxiety and depression on outcomes of patients with coronary artery disease. Arch Intern Med (2000) 2.34
Randomised trial of fish oil for prevention of restenosis after coronary angioplasty. Lancet (1989) 2.28
Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res (1985) 2.23
Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med (1998) 2.22
Evidence implicating nonmuscle myosin in restenosis. Use of in situ hybridization to analyze human vascular lesions obtained by directional atherectomy. Circulation (1992) 2.20
Cost-effectiveness of a smoking cessation program after myocardial infarction. J Am Coll Cardiol (1993) 2.18
Cardiac involvement in mitochondrial diseases. A study on 17 patients with documented mitochondrial DNA defects. Circulation (1995) 2.15
Effect of reperfusion on biventricular function and survival after right ventricular infarction. N Engl J Med (1998) 2.12
Interactions of Porphyromonas gingivalis with epithelial cells. Infect Immun (1993) 2.12
Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet (1993) 2.12
Selection of patients for coronary angiography and coronary revascularization early after myocardial infarction: is there evidence for a gender bias? Ann Intern Med (1992) 2.11
Meeting highlights. Highlights of the 48th scientific sessions of the American College of Cardiology. Circulation (1999) 2.10
The creatine kinase system in normal and diseased human myocardium. N Engl J Med (1985) 2.06
Transcatheter closure of ventricular septal defects. Circulation (1988) 2.05
Hemodynamic assessment of amrinone. A new inotropic agent. N Engl J Med (1978) 2.03
Regional right ventricular dysfunction detected by echocardiography in acute pulmonary embolism. Am J Cardiol (1996) 2.01
Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer (2007) 2.00
Balloon dilatation of calcific aortic stenosis in elderly patients: postmortem, intraoperative, and percutaneous valvuloplasty studies. Circulation (1986) 2.00
Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation (1985) 1.92
Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med (1992) 1.92
Reflex increase in coronary vascular resistance in patients with ischemic heart disease. N Engl J Med (1976) 1.92
Cardiac hypertrophy: useful adaptation or pathologic process? Am J Med (1980) 1.87
Yeast malate dehydrogenase: enzyme inactivation in catabolite repression. Eur J Biochem (1967) 1.85
Isolated systolic hypertension : prognostic information provided by pulse pressure. Hypertension (1999) 1.83
The use of nicotine-replacement therapy by hospitalized smokers. Am J Prev Med (1999) 1.78
Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation (1987) 1.78
Predictors of event-free survival after balloon aortic valvuloplasty. N Engl J Med (1991) 1.78
Contractile state of the left ventricle in man as evaluated from end-systolic pressure-volume relations. Circulation (1977) 1.77
Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J (1999) 1.76
Severe autologous GVHD after hematopoietic progenitor cell transplantation for multiple myeloma. Bone Marrow Transplant (2008) 1.72
Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest (1994) 1.69
Perforations after percutaneous coronary interventions: clinical, angiographic, and therapeutic observations. Cathet Cardiovasc Diagn (1994) 1.68
Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol (1998) 1.67
Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation (1994) 1.67
Percutaneous balloon mitral valvuloplasty in a pregnant woman with mitral stenosis. Cathet Cardiovasc Diagn (1988) 1.65
Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reverse. Circulation (1998) 1.64
Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation (1998) 1.63
Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. J Am Coll Cardiol (1994) 1.61
Diastolic properties of the left ventricle. Ann Intern Med (1976) 1.59
Generalized peritonitis with pneumoperitoneum caused by the spontaneous perforation of pyometra without malignancy: report of a case. Surg Today (1999) 1.56
Attenuating effect of H+K+ATPase inhibitors on airway cough hypersensitivity induced by allergic airway inflammation in guinea-pigs. Clin Exp Allergy (2005) 1.56
Independent prognostic information provided by sphygmomanometrically determined pulse pressure and mean arterial pressure in patients with left ventricular dysfunction. J Am Coll Cardiol (1999) 1.56
Left ventricular diastolic pressure-volume relations in rats with healed myocardial infarction. Effects on systolic function. Circ Res (1981) 1.55
Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Cathet Cardiovasc Diagn (1996) 1.54
Cost-effectiveness of captopril therapy after myocardial infarction. J Am Coll Cardiol (1995) 1.52
Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. Cathet Cardiovasc Diagn (1992) 1.52
Current complications of diagnostic and therapeutic cardiac catheterization. J Am Coll Cardiol (1988) 1.51
Validity of an indirect tail-cuff method for determining systolic arterial pressure in unanesthetized normotensive and spontaneously hypertensive rats. J Lab Clin Med (1971) 1.51
Enhanced intracoronary thrombolysis with urokinase using a novel, local drug delivery system. In vitro, in vivo, and clinical studies. Circulation (1995) 1.50
Non-invasive detection of endothelial dysfunction with 30 MHz transducer. Lancet (1996) 1.50
Aspirin-triggered resolvin D1 reduces mucosal inflammation and promotes resolution in a murine model of acute lung injury. Mucosal Immunol (2012) 1.49
Late prognosis of acute pulmonary embolism. N Engl J Med (1973) 1.47
Pulsatile hemodynamics in congestive heart failure. Hypertension (2001) 1.44
Activated clotting times in acute coronary syndromes and percutaneous transluminal coronary angioplasty. Cathet Cardiovasc Diagn (1995) 1.44
Significance of nitroglycerin-induced hypotension with inferior wall acute myocardial infarction. Am J Cardiol (1989) 1.44
Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol (1995) 1.43
High-density lipoprotein subfractions. Am J Med (1993) 1.42
Atrial natriuretic factor gene expression in ventricles of rats with spontaneous biventricular hypertrophy. J Clin Invest (1988) 1.42
Variations in cholesterol management practices of U.S. physicians. J Am Coll Cardiol (1997) 1.42
Activation of the cortical and medullary dopaminergic systems by nitrous oxide in rats: a possible neurochemical basis for psychotropic effects and postanesthetic nausea and vomiting. Anesth Analg (1994) 1.41
Problems on the pathway from risk assessment to risk reduction. Circulation (1998) 1.41